Shire Pharmaceuticals Group plc Initiates Two Adult ADHD Outreach Programs
Published: Aug 17, 2009
PHILADELPHIA, Aug. 17 /PRNewswire-FirstCall/ -- Shire plc, the global specialty biopharmaceutical company, today announced two initiatives reinforcing their commitment to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral disorder that affects an estimated 10 million adults across the country.* The first initiative, "RoADHD Trip," a multi-city self screening tour, will visit eight cities across the country in an effort to raise awareness that ADHD in adults is a real and treatable medical disorder. The second initiative, ADHD Clinical Education (ACE) Program, includes a field-based team of experienced psychiatric nurses who will provide in-office education to physicians and their staff on ADHD in adults.